E-mail a Wiley Online Library Link

Melissa L. Johnson, Camelia S. Sima, Jamie Chaft, Paul K. Paik, William Pao, Mark G. Kris, Marc Ladanyi and Gregory J. Riely Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas Cancer 119

Version of Record online: 18 JUL 2012 | DOI: 10.1002/cncr.27730

Lung adenocarcinomas can be distinguished by identifying mutated driver oncogenes, including epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma 2 viral oncogene homolog (KRAS). In the largest cohort of patients whose tumors were analyzed for EGFR and KRAS mutations from 1 institution, the authors report that the presence of a KRAS mutation is a poor prognostic factor for advanced lung adenocarcinomas.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field